Panbela Therapeutics, Inc. (NASDAQ:PBLA – Get Free Report) dropped 9.1% during mid-day trading on Friday . The company traded as low as $0.39 and last traded at $0.41. Approximately 2,947 shares traded hands during mid-day trading, a decline of 89% from the average daily volume of 27,623 shares. The stock had previously closed at $0.45.
Panbela Therapeutics Stock Down 9.1 %
The company has a market capitalization of $1.99 million, a price-to-earnings ratio of -0.01 and a beta of 1.56. The business has a 50-day moving average price of $0.34 and a 200-day moving average price of $0.35.
About Panbela Therapeutics
Panbela Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company’s lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial.
Featured Articles
- Five stocks we like better than Panbela Therapeutics
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Cold Front, Hot Stocks: Diesel Prices Propel Energy Leaders
- When to Sell a Stock for Profit or Loss
- Sustainable and Successful: 3 Climate ETFs Beating the Market
- Using the MarketBeat Stock Split Calculator
- Quantum Opportunity: Skywater Technology’s Long-Term Potential
Receive News & Ratings for Panbela Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Panbela Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
